Why You Can't Sleep on Peptides

Your body has one job while you sleep: keep your blood sugar stable enough that your brain stays quiet and your stress hormones stay low. When that system works, you sleep through the night. When it breaks down, your body pulls the alarm, and you wake up at 2 or 3 in the morning feeling wired and anxious without knowing why.

That alarm is cortisol, and it is doing exactly what it is supposed to do.

When blood glucose drops below a certain threshold during sleep, your body treats it as a metabolic emergency and releases cortisol and adrenaline to trigger something called gluconeogenesis, which is the process where your liver manufactures new glucose to bring blood sugar back up. The problem is that cortisol is a stimulating hormone, and once it spikes, sleep is over. You are not waking up because something is wrong with your sleep. You are waking up because your body just ran a rescue operation.

Peptides can trigger that rescue operation through two completely different mechanisms depending on what you are taking, and understanding which one applies to you is the whole key.

The first mechanism involves incretins, the class of drugs that includes semaglutide, tirzepatide, and retatrutide. These compounds work by mimicking gut hormones that signal fullness and regulate insulin, and they are extraordinarily effective at suppressing appetite. In the phase 2 trial for retatrutide, participants at the 12mg dose lost an average of 24.2% of their body weight, which tells you something about how aggressively these drugs reduce caloric intake. The appetite suppression is not subtle.

The problem is that most people do not realize how little they are eating until they look at the numbers. You feel satisfied. You are not hungry. So you eat less, sometimes far less than you need. And when you go to sleep with very little fuel stored from the day, your blood glucose has a short runway before it drops into that emergency zone. The drug did not directly cause your blood sugar to crash. The drug caused you to undereat, and undereating caused the crash.

The second mechanism is entirely different and involves a class of compounds called GH secretagogues, which includes peptides like CJC-1295, ipamorelin, and tesamorelin. These work by stimulating your pituitary gland to release growth hormone, and most people inject them before bed because that is when the body's natural GH pulse is largest and the timing creates a kind of amplifying effect.

Here is where the biology gets specific. Growth hormone is anti-insulin by design, meaning one of its primary jobs is to oppose insulin's effects on glucose uptake so that during periods of high GH output, glucose stays available in the bloodstream for fuel. The research on this goes back to work on the dawn phenomenon, a well-documented pattern in diabetics where nocturnal GH spikes cause hepatic glucose production to increase by roughly 30%. When researchers suppressed those nocturnal GH spikes with somatostatin, the dawn phenomenon disappeared entirely. When they artificially restored the spikes, it came back. The mechanism is clear: GH drives insulin resistance at the liver and in peripheral tissues by increasing free fatty acid flux and reducing insulin sensitivity, which creates a glucose swing during the night.

When you inject a GH secretagogue before bed and that pulse fires during deep sleep, you are getting the same effect. Not a diabetic level of disruption, but a blood sugar swing large enough to cross that emergency threshold and trigger the cortisol rescue.

If you are on both an incretin and a GH secretagogue, both mechanisms are running at the same time. Lower fuel stores from undereating on top of a GH-driven blood sugar swing is a compounding problem.

So what do you actually do about it.

If you are on an incretin and barely eating, the fix is straightforward: you need to eat enough during the day that your body has something to work with overnight. This does not mean eating when you are not hungry. It means being deliberate about hitting a caloric floor even when the drug is suppressing the signal to eat. If you are eating low-carb or ketogenic, this concern applies less directly because your body shifts to running on fat and ketones overnight, and gluconeogenesis from protein maintains blood glucose without relying on stored glycogen. The issue is not the macronutrient split. The issue is total caloric insufficiency, where a drug kills appetite so effectively that someone ends up in a severe deficit with no metabolic buffer going into the night.

If the problem is a GH secretagogue, the first adjustment to try is moving the injection a couple of hours earlier in the evening rather than immediately before bed. This shifts the timing of the GH pulse so the peak and the subsequent blood sugar swing happen earlier in the sleep cycle when you are more likely to sleep through it naturally, rather than hitting at the phase of sleep when cortisol is already beginning its natural morning rise.

A small snack of protein and fat before bed works as a buffer in both scenarios. Fat slows gastric emptying and extends the slow release of energy across the night, and protein gives the liver substrate for gluconeogenesis so it does not have to work as hard. This is not a large meal. It is a buffer, something in the range of 150 to 250 calories with minimal carbohydrate to avoid an insulin spike that would accelerate the drop.

Most people chasing better sleep on peptides are looking at their sleep stack when they should be looking at their plate.

---

References

1. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness